Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 15, 2018Journal of Hematology & OncologyOpen Access

Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAnnalisa RuggeriEuropean Organisation for Rare DiseasesMLMyriam LabopinInserm
Andrea Bacigalupo
Andrea BacigalupoUniversité Claude Bernard Lyon 1

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ruggeri et al. (2018) studied this question.

synapsesocial.com/papers/6a1068182badbc352afff37dhttps://doi.org/10.1186/s13045-018-0586-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide2017 · 92 citations
  2. 2OCTET ‐ CY : a phase II study to investigate the efficacy of post‐transplant cyclophosphamide as sole graft‐versus‐host prophylaxis after allogeneic peripheral blood stem cell transplantation2015 · 69 citations
  3. 3National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report2005 · 3,579 citations
  4. 4Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation2016 · 235 citations